1.
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
by Ungar, Bella
Gut, 2014, Vol.63 (8), p.1258-1264
2.
3.
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
by Garcês, Sandra
Annals of the rheumatic diseases, 2013, Vol.72 (12), p.1947-1955
4.
Prenatal Stress-Induced Increases in Placental Inflammation and Offspring Hyperactivity Are Male-Specific and Ameliorated by Maternal Antiinflammatory Treatment
by Bronson, Stefanie L
Endocrinology (Philadelphia), 2014, Vol.155 (7), p.2635-2646
5.
6.
Diagnosis and management of drug hypersensitivity reactions
by Romano, Antonino, MD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.S67-S73
7.
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
by Vande Casteele, N.
Alimentary pharmacology & therapeutics, 2012, Vol.36 (8), p.765-771
8.
Clinical and pathologic perspectives on aspirin sensitivity and asthma
by Stevenson, Donald D
Journal of allergy and clinical immunology, 2006, Vol.118 (4), p.773-786
9.
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment
by Imaeda, Hirotsugu
Journal of gastroenterology, 2013, Vol.49 (4), p.674-682
10.
Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease
by Lee, Jennifer Y., MD
Journal of allergy and clinical immunology, 2007, Vol.119 (1), p.157-164
11.
Immunogenicity to infliximab is associated with HLA-DRB1
by Billiet, Thomas
Gut, 2015, Vol.64 (8), p.1344-1345
12.
The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis
by Harnett, M M
Annals of the rheumatic diseases, 2008, Vol.67 (4), p.518-523
13.
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
by Vande Casteele, N
Gut, 2012, Vol.61 (2), p.321-321
14.
In vitro Diagnosis of Immediate Drug Hypersensitivity: Should We Go with the Flow?
by Mangodt, Evelyne A
International archives of allergy and immunology, 2015, Vol.168 (1), p.3-12
15.
Selection of patients for aspirin desensitization treatment
by Stevenson, Donald D
Journal of allergy and clinical immunology, 2006, Vol.118 (4), p.801-804
16.
An autoimmune double attack
by Fuchs, Tina
The Lancet (British edition), 2012, Vol.379 (9823), p.1364-1364
17.
Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease
by Woessner, Katharine M., MD, FAAAAI
Journal of allergy and clinical immunology, 2013, Vol.133 (1), p.286-287.e9
18.
The Role of IgA and IgA Fc Receptors as Anti-Inflammatory Agents
by Monteiro, Renato C
Journal of clinical immunology, 2010, Vol.30 (Suppl 1), p.61-64
19.
Polymorphisms of the CYP2C19 gene in Japanese patients with aspirin-exacerbated respiratory disease
by Kohyama, Kenya, MD
Journal of allergy and clinical immunology, 2011, Vol.128 (5), p.1117-1120
20.
Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review
by Mishra, L C
Alternative medicine review, 2000, Vol.5 (4), p.334
